Research programme: glycan based therapeutics - CHO Pharma

Drug Profile

Research programme: glycan based therapeutics - CHO Pharma

Alternative Names: CHO S05; CHO V07; Dual-effect anti-flu drugs

Latest Information Update: 20 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Academia Sinica
  • Developer CHO Pharma
  • Class Antivirals; Vaccines
  • Mechanism of Action Cytokine inhibitors; Influenza A virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Influenza virus infections

Most Recent Events

  • 20 Jul 2017 CHO Pharma has patent protection for glycan based vaccine and drugs in USA, Europe, South Korea, Japan, Canada, China and Australia (CHO Pharma website, July 2017)
  • 20 Jul 2017 CHO Pharma has patents pending for glycan based vaccine and drugs in Taiwan (CHO Pharma website, July 2017)
  • 20 Jul 2017 Preclinical trials in Influenza virus infections in Taiwan (PO) (CHO Pharma pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top